These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25213406)

  • 1. Maximal immune response and cross protection by influenza virus nucleoprotein derived from E. coli using an optimized formulation.
    Wang W; Huang B; Jiang T; Wang X; Qi X; Tan W; Ruan L
    Virology; 2014 Nov; 468-470():265-273. PubMed ID: 25213406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant.
    Zheng M; Liu F; Shen Y; Wang S; Xu W; Fang F; Sun B; Xie Z; Chen Z
    Hum Vaccin Immunother; 2015; 11(2):397-406. PubMed ID: 25607884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli.
    Wang W; Huang B; Jiang T; Wang X; Qi X; Gao Y; Tan W; Ruan L
    PLoS One; 2012; 7(12):e52488. PubMed ID: 23285063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IRES-based co-expression of influenza virus conserved genes can promote synergistic antiviral effects both in vitro and in vivo.
    Khodamoradi S; Shenagari M; Kheiri MT; Sabahi F; Jamali A; Heidari A; Ashrafkhani B
    Arch Virol; 2018 Apr; 163(4):877-886. PubMed ID: 29270718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge.
    Fu TM; Guan L; Friedman A; Schofield TL; Ulmer JB; Liu MA; Donnelly JJ
    J Immunol; 1999 Apr; 162(7):4163-70. PubMed ID: 10201942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein.
    Tamura S; Miyata K; Matsuo K; Asanuma H; Takahashi H; Nakajima K; Suzuki Y; Aizawa C; Kurata T
    J Immunol; 1996 May; 156(10):3892-900. PubMed ID: 8621928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of nucleoprotein to chemokine receptors by DNA vaccination results in increased CD8(+)-mediated cross protection against influenza.
    Baranowska M; Hauge AG; Hoornaert C; Bogen B; Grødeland G
    Vaccine; 2015 Dec; 33(49):6988-96. PubMed ID: 26387432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.
    Wang W; Li R; Deng Y; Lu N; Chen H; Meng X; Wang W; Wang X; Yan K; Qi X; Zhang X; Xin W; Lu Z; Li X; Bian T; Gao Y; Tan W; Ruan L
    Clin Vaccine Immunol; 2015 Jun; 22(6):618-30. PubMed ID: 25834017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge.
    Kheiri MT; Jamali A; Shenagari M; Hashemi H; Sabahi F; Atyabi F; Saghiri R
    Antiviral Res; 2012 Sep; 95(3):229-36. PubMed ID: 22809863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Fang F; Zheng M; Chen Z
    Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
    Altstein AD; Gitelman AK; Smirnov YA; Piskareva LM; Zakharova LG; Pashvykina GV; Shmarov MM; Zhirnov OP; Varich NP; Ilyinskii PO; Shneider AM
    Arch Virol; 2006 May; 151(5):921-31. PubMed ID: 16292596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge.
    Gao X; Wang W; Li Y; Zhang S; Duan Y; Xing L; Zhao Z; Zhang P; Li Z; Li R; Wang X; Yang P
    Antiviral Res; 2013 Apr; 98(1):4-11. PubMed ID: 23416215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved immune response to recombinant influenza nucleoprotein formulated with ISCOMATRIX.
    Cargnelutti DE; Sanchez MV; Alvarez P; Boado L; Glikmann G; Mattion N; Scodeller EA
    J Microbiol Biotechnol; 2012 Mar; 22(3):416-21. PubMed ID: 22450799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
    Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity.
    Ohba K; Yoshida S; Zahidunnabi Dewan M; Shimura H; Sakamaki N; Takeshita F; Yamamoto N; Okuda K
    Vaccine; 2007 May; 25(21):4291-300. PubMed ID: 17403560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein.
    Guo L; Zheng M; Ding Y; Li D; Yang Z; Wang H; Chen Q; Sui Z; Fang F; Chen Z
    Arch Virol; 2010 Nov; 155(11):1765-75. PubMed ID: 20652335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insect cell-expressed hemagglutinin with CpG oligodeoxynucleotides plus alum as an adjuvant is a potential pandemic influenza vaccine candidate.
    Gong M; Zhou J; Yang C; Deng Y; Zhao G; Zhang Y; Wang Y; Zhou Y; Tan W; Xu H
    Vaccine; 2012 Dec; 30(52):7498-505. PubMed ID: 23116697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune protective effectiveness of seasonal influenza spilt vaccine against homologous and heterogonous subtypes of influenza virus in mice].
    Huang BY; Wang XP; Wang WL; Hu W; Gao Q; Tan WJ; Ruan L
    Bing Du Xue Bao; 2011 May; 27(3):265-73. PubMed ID: 21774253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.